Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme
Goal is to improve access to replacement therapies for coagulation disorders in Europe
Kedrion Biopharma joins IPOPI in supporting patients with APP PID Genius
This new APP, presented at the IPIC Congress in Dubai, will be the personal assistant to people living with PIDs
Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy
Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells
Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®
The product is approved for post-exposure prophylaxis against rabies infection
Kedrion Biopharma attends XXVI ISTH Congress in Berlin, Germany
A crowded symposium dedicated to the SIPPET Study was held on July 9th
Farmindustria roadshow is hosted by Kedrion
Innovation and Production of Value held on 19th May at our Bolognana production plant
Kedrion Biopharma joins IPOPI in celebrating World PI Week 2017
Global campaign to improve early diagnosis and optimal treatments for PID
Kedrion Biopharma signs agreement with European Hemophilia Consortium (EHC)
The agreement aims to improve patient access to coagulation disorders treatments in Europe
Kedrion Biopharma initiatives for World Hemophilia Day 2017
The goal is to provide wider access to plasma-derived therapies for coagulation disorders the world over
New company AO Kirov Plasma established in Russia
It’s a joint venture between Kedrion Biopharma, Nacimbio and Pharmastandard